Menstrual and women's health is the main area connected here, and any felt benefit should be read together with the human evidence base.
Some human supplement-context evidence is present and directly informs the score.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Pain and headache. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.
Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.
Symptoms or adverse events reported in studies of this ingredient without another active ingredient.
These studies reported a negative change, reduced absorption, or another caution when substances were used together. They do not predict an individual outcome.
Paper IDs and full lists are private. Only study types and summaries are shown.
The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins, and is associated with a lower final cognitive test scores.
The clinical and biochemical features of disorders leading to B6‐responsive seizures and the treatment of these disorders are described in this review.
These randomized trial data from a large cohort of women at high risk of CVD indicate that daily supplementation with folic acid/B6/B12 may reduce the risk of age-related macular degeneration.
High-dose B vitamin supplementation significantly reduces progression of early-stage subclinical atherosclerosis (carotid artery intima media thickness) in well-nourished healthy B vitamin “replete” individuals at low risk for cardiovascular disease with a fas
The first animal model for PDE is reported, an aldh7a1-null zebrafish displaying deficient lysine metabolism and spontaneous and recurrent seizures in the larval stage (10 days postfertilization), which provides valuable insights into PDE pathophysiology.
Both low and high plasma PLP were associated with a significant suppression of molecular and histological markers of inflammation in the colon and, if confirmed, vitamin B6 supplementation may offer an additional tool for the management of IBD.